[Nucala ISS/SCS Committee. Last updated in June 2022.]
GSK call for research proposals of relevance to disease understanding and impact of mepolizumab in two disease areas:
• Severe eosinophilic asthma (SEA)
• Hypereosinophilic syndrome (HES)
Applications are invited in the following areas:
• Impact of mepolizumab on prevention of organ damage and disease progression
• Composite outcomes with real-world use of mepolizumab, such as remission
• Patient identification biomarkers of those at risk of worse long-term clinical outcomes
• Non-eosinophilic biological effects of interleukin 5 (IL-5)
• CNS assessment of mechanisms of mepolizumab in promoting “well-being”

[Daprodustat ISS/SCS Committee. Last updated in May 2022.]
• Clinical practices and behaviours related to the management of anemia of CKD
• Healthcare resource utilisation related to anemia of CKD
• Burden and impact of untreated anemia of CKD across different geographies or related to differential healthcare access, including underserved populations
• Novel technologies to improve patient care and/or the patient experience in the management of anemia of CKD
• Effectiveness of Daprodustat in subgroups of special interest
Including patients not reaching Hb target, inflamed patients, diabetic patients, anephritic patients, home dialysis, peritoneal dialysis, transplant
• New indications (other than anemia of CKD), where Daprodustat could benefit patients